Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/
Teva Pharmaceuticals의 시장 확장을 추적하고 있습니다
최근 90일간 시그널 66건.
Teva Pharmaceuticals의 글로벌 확장이 경쟁사와 비교해 어떤지
Teva Pharmaceuticals본 회사막대는 비교 대상 회사 간 상대적 규모를 나타냅니다.
열5| 회사 | 시장 | 신규 시장 | 모멘텀 | 활동 | 확장 점수 |
|---|---|---|---|---|---|
 Teva Pharmaceuticals본 회사 | 0 | 0 | — | 0 | 0 |
Quality Control Analyst I
공고 보기Kfar Saba, Center District, Israel · 그저께
Sr Director Supply Chain
공고 보기Dupnitsa, Kyustendil, Bulgaria · 3일 전
Manager, Category Excellence / Capability Lead ExM GP
공고 보기Sofia, Sofia City, Bulgaria · 3일 전
Today, we announced Teva Pharmaceuticals’ Q1 2026 financial results, marking a strong start to the year and reinforcing our transformation into a leading biopharma company.Our key innovative products are becoming an engine of sustainable growth, collectively growing 41% year-over-year in local currency and continuing to shift Teva’s portfolio mix. We also saw continued progress on our late-stage innovative pipeline and stable generics performance driven by biosimilars growth. That's what our Piv ...
진행 중
Explore open roles at Teva India >>
진행 중
This post is directed to HCPs only.Looking for expert perspectives on the evolving role of long-acting injectables (LAIs) in improving the lives of people living with schizophrenia?Come along to the Forum Hall at 13.15 on Sunday 29th March during EPA 2026 in Prague to hear from an expert faculty as they consider the evolving evidence, opinion and guidelines supporting the wider integration of LAIs into clinical practice.13.15-14.15, Forum Hall (second floor)https://lnkd.in/eqRnEUpf Please do n ...
종료됨텔아비브 증권거래소 상승, Tower Semiconductor과 Teva 주도. Bank Leumi 높은 거래량으로 하락.
테바 제약은 3년 연속 성장 후 2026년 매출과 이익 감소를 전망하며, 예상 매출은 164-168억 달러, EPS는 2.55-2.65달러로 예상됩니다.
Teva 제약의 API 부문은 운영 조정의 일환으로 2년에 걸쳐 이스라엘에서 250개 일자리를 삭감하며, 주로 베르셰바 인근 Neot Hovav 공장에 영향을 미친다.
인증된 이메일과 직통 전화 잠금 해제
무료 · 신용카드 불필요
Teva Pharmaceuticals의 사업, 시장, 성장 시그널에 대한 빠른 답변입니다.
© 2026 Pubrio. 모든 권리 보유.
